Shares of Inventiva S.A. (NASDAQ:IVA – Get Free Report) dropped 2.8% on Tuesday . The company traded as low as $2.11 and last traded at $2.11. Approximately 5,585 shares were traded during mid-day trading, an increase of 7% from the average daily volume of 5,223 shares. The stock had previously closed at $2.17.
Analyst Ratings Changes
Several brokerages recently issued reports on IVA. HC Wainwright cut their price objective on Inventiva from $14.00 to $13.00 and set a “buy” rating for the company in a research report on Tuesday, October 15th. UBS Group began coverage on Inventiva in a report on Tuesday, November 12th. They issued a “neutral” rating and a $3.00 price target for the company. Finally, Stifel Nicolaus decreased their price objective on Inventiva from $20.00 to $17.00 and set a “buy” rating on the stock in a research note on Friday, November 22nd.
View Our Latest Stock Report on Inventiva
Inventiva Stock Performance
About Inventiva
Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.
Featured Stories
- Five stocks we like better than Inventiva
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- The Fed Is More Likely to Hike Than Cut Rates in 2025
- What is a SEC Filing?
- Investors Navigate Uncertainty by Seeking Refuge in Gold and Oil
- Golden Cross Stocks: Pattern, Examples and Charts
- Archer Aviation Shares Slide, Now Bargain Priced for 2025
Receive News & Ratings for Inventiva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inventiva and related companies with MarketBeat.com's FREE daily email newsletter.
